Evidence map›Paper›PMID 38378595›Full record

ArticleOrphanet journal of rare diseases2024

Phenylketonuria from the perspectives of patients in Türkiye.

Merve Esgi, Hakan Ergun, Nazmi Yalcin Kaya, Deniz Yilmaz Atakay, Ege Erucar, Fatma Celik

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Merve EsgiDepartment of Nutrition and Dietetics, Faculty of Health Sciences, Kocaeli University, Kocaeli, Türkiye. dyt.merveesgi@gmail.com.ORCID 0000-0002-4968-9828
Hakan ErgunDepartment of Medical Pharmacology, Ankara University Faculty of Medicine, Ankara, Türkiye.ORCID 0000-0002-7839-966X
Nazmi Yalcin KayaOmega-HelCon, Ankara, Türkiye.ORCID 0000-0001-5234-4559
Deniz Yilmaz AtakayPKU Family Association, Istanbul, Türkiye.ORCID 0000-0002-9844-6881
Ege ErucarFaculty of Medicine, Altinbas University, Istanbul, Türkiye.ORCID 0000-0003-2889-1979
Fatma CelikFood and Drug Department, Parma University, Parma, Italy.ORCID 0000-0002-3076-4074
Altınbaş University · TRAnkara University · TRKocaeli Üniversitesi · TROmega Consult (Slovenia) · SIUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe present study aimed to determine the problems, unmet needs and expectations of phenylketonuria (PKU) patients in Türkiye regarding follow-up and treatment in order to provide data for future planning and implementations on PKU.

methodsThe study included patients diagnosed with PKU and/or their parents. They were informed about the study via phone calls and their verbal consents were obtained. Questions in the data collection forms, which were established separately for pediatric, adolescent, and adult age groups, were applied during the interviews and the answers were recorded.

resultsAmong 182 classical PKU patients, 66 (36.3%) were in the pediatric group (0-12 years old), 44 (24.2%) were in the adolescent group (13-19 years old), and 72 (39.5%) were in the adult group (≥ 20 years old). In all patient groups, phenylalanine-restricted diet and medical nutrition products were the main options for treatment. The median of the last measured blood phenylalanine concentration (patient-reported) was 290 µmol/L, 425 µmol/L, and 750 µmol/L in the pediatric, adolescent, and adult groups, respectively. The frequency of blood testing for serum phenylalanine level according to the age groups was appropriate in nearly half of the patients. While the majority of the patients have been visiting the metabolism center they have been diagnosed with PKU for control, considerable proportion of the patients would like to change the center or the doctor they visit for control if they could. It was determined that nearly half of the patients had trouble in accessing the metabolism center. Treatment options' being limited and expensive were the major problems. The main requests of the patients and patient relatives included easier access to the metabolism centers and more options for treatment and diet.

conclusionsAccess to the services should be easier to improve the patients' follow-up and treatment. There is need for low-cost, easily applicable, and accessible nutrition products and effective novel pharmacological agents. Focusing on these issues in health policies by providing pedagogic/psychological support, establishing support programs also comprising the families, and increasing the awareness activities were the key outcomes.

Indexed as

PhenylketonuriasAdolescentAdultChildChild, PreschoolData CollectionDietHumansInfantInfant, NewbornPhenylalanineTurkeyYoung AdultPhenylalanineMedical nutrition productsNew treatmentsPhenylalanine-restricted dietPhenylketonuriaUnmet needs

Identifiers

PMID38378595
PMCPMC10880278
OpenAlexW4391955599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.